Arbor Trust Wealth Advisors LLC Sells 3,625 Shares of Pfizer Inc. (NYSE:PFE)

Arbor Trust Wealth Advisors LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 19.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,874 shares of the biopharmaceutical company’s stock after selling 3,625 shares during the quarter. Arbor Trust Wealth Advisors LLC’s holdings in Pfizer were worth $428,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in PFE. RB Capital Management LLC raised its position in shares of Pfizer by 6.7% during the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after acquiring an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. raised its position in shares of Pfizer by 1.1% during the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after acquiring an additional 400 shares during the last quarter. United Bank raised its position in shares of Pfizer by 0.6% during the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after acquiring an additional 290 shares during the last quarter. Ergoteles LLC raised its position in shares of Pfizer by 136.3% during the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after acquiring an additional 21,209 shares during the last quarter. Finally, Mackenzie Financial Corp raised its position in shares of Pfizer by 6.4% during the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after acquiring an additional 79,887 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 0.8 %

Shares of NYSE:PFE traded down $0.22 during mid-day trading on Tuesday, hitting $25.69. 28,601,821 shares of the company traded hands, compared to its average volume of 42,553,457. The stock has a market cap of $145.47 billion, a P/E ratio of 71.69, a P/E/G ratio of 1.16 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 12-month low of $25.61 and a 12-month high of $41.33. The stock has a 50-day moving average price of $27.27 and a two-hundred day moving average price of $28.84.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. Pfizer’s quarterly revenue was down 41.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.14 earnings per share. On average, equities research analysts forecast that Pfizer Inc. will post 2.22 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a report on Thursday, January 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday. Twelve equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $36.88.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.